NMS·Healthcare·$189M·#443 / 520 in Healthcare
CRBU Caribou Biosciences, Inc.
24HIGH RISK
CATEGORY BREAKDOWN
GROWTH19
QUALITY0
STABILITY29
VALUATION20
GOVERNANCE61
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+11.7%
19
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
1 months
2
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
22.3%
82
< 25% strong
Price / Sales
Market cap relative to trailing revenue
17.0x
20
< 3x strong
Rule of 40
Growth rate plus operating margin
-1209
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
9.0%
60
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+6.1%
63
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE CRBU WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when CRBU's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.